Allena Pharmaceuticals, Inc. (ALNA) financial statements (2021 and earlier)

Company profile

Business Address ONE NEWTON EXECUTIVE PARK
NEWTON, MA 02462
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35306294
Cash and cash equivalents35306294
Other undisclosed current assets2332
Total current assets:37336496
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment1010
Other noncurrent assets0000
Total noncurrent assets:2110
TOTAL ASSETS:39346596
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6664
Accounts payable2322
Accrued liabilities3342
Debt 4 4
Other undisclosed current liabilities0   
Total current liabilities:61168
Noncurrent Liabilities
Long-term debt and lease obligation106106
Long-term debt, excluding current maturities106106
Operating lease, liability00
Liabilities, other than long-term debt  00
Other liabilities  00
Other undisclosed noncurrent liabilities(0)   
Total noncurrent liabilities:106106
Total liabilities:16171613
Stockholders' equity
Stockholders' equity attributable to parent23174983
Common stock0000
Additional paid in capital220182167165
Accumulated deficit(198)(165)(118)(82)
Total stockholders' equity:23174983
TOTAL LIABILITIES AND EQUITY:39346596

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(32)(48)(36)(21)
Operating loss:(32)(48)(36)(21)
Nonoperating income (expense)(1)0(0)(1)
Investment income, nonoperating(1)01(0)
Other nonoperating expense(0)(0)(0)(0)
Interest and debt expense  (1) 
Loss before gain (loss) on sale of properties:(33)(47)(36)(22)
Other undisclosed net income  1 
Net loss attributable to parent:(33)(47)(36)(22)
Preferred stock dividends and other adjustments   (0)
Net loss available to common stockholders, diluted:(33)(47)(36)(22)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(33)(47)(36)(22)
Comprehensive loss, net of tax, attributable to parent:(33)(47)(36)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: